Cinemark Holdings, Inc. (CNK)
NYSE: CNK · Real-Time Price · USD
24.92
-0.58 (-2.27%)
At close: Aug 6, 2025, 4:00 PM
25.41
+0.49 (1.97%)
After-hours: Aug 6, 2025, 7:36 PM EDT
Revance Therapeutics Stock Forecast
Stock Price Forecast
The 13 analysts that cover Revance Therapeutics stock have a consensus rating of "Buy" and an average price target of $33.46, which forecasts a 34.27% increase in the stock price over the next year. The lowest target is $20 and the highest is $37.
Price Target: $33.46 (+34.27%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Revance Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 3 | 3 |
| Buy | 5 | 5 | 6 | 6 | 7 | 7 |
| Hold | 3 | 3 | 3 | 3 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 11 | 11 | 12 | 12 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Roth Capital | Roth Capital | Strong Buy Maintains $36 → $34 | Strong Buy | Maintains | $36 → $34 | +36.44% | Aug 4, 2025 |
| Barrington Research | Barrington Research | Buy Reiterates $36 | Buy | Reiterates | $36 | +44.46% | Aug 4, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $36 → $33 | Buy | Maintains | $36 → $33 | +32.42% | Aug 4, 2025 |
| Wedbush | Wedbush | Hold → Buy Upgrades $32 → $37 | Hold → Buy | Upgrades | $32 → $37 | +48.48% | Jul 11, 2025 |
| Deutsche Bank | Deutsche Bank | Strong Buy Initiates $36 | Strong Buy | Initiates | $36 | +44.46% | Jul 10, 2025 |
Financial Forecast
Revenue This Year
3.31B
from 3.05B
Increased by 8.41%
Revenue Next Year
3.56B
from 3.31B
Increased by 7.74%
EPS This Year
1.73
from 2.06
Decreased by -16.08%
EPS Next Year
2.33
from 1.73
Increased by 34.94%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 3.5B | 4.0B | 4.1B |
| Avg | 3.3B | 3.6B | 3.7B |
| Low | 3.1B | 3.3B | 3.4B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 15.0% | 20.5% | 16.0% |
| Avg | 8.4% | 7.7% | 4.0% |
| Low | 2.0% | 1.2% | -3.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 2.04 | 2.93 | 3.28 |
| Avg | 1.73 | 2.33 | 2.69 |
| Low | 1.25 | 1.54 | 2.01 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -1.0% | 69.6% | 40.6% |
| Avg | -16.1% | 34.9% | 15.5% |
| Low | -39.1% | -10.9% | -13.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.